Clinical Trial Update: Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone [Phase 2]

View source ↗

Summary

Phase 2 trial comparing standard dose, high dose, and extended standard dose of Radium-223 dichloride in metastatic castration-resistant prostate cancer with bo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2018-07-12